REdI 2024 | D1S08: Boosting Diversity in Clinical Trials 🌍

This presentation emphasized the importance of increasing diversity in clinical studies and outlined FDA's initiative to enhance diversity in drug development programs. The session provided an overview of Drug Trials Snapshots and explained how this tool supports transparency in clinical trial demographics. Key strategies for promoting diversity in clinical trials were discussed from the Drug Trials Snapshots perspective to improve representation in pharmaceutical research.

Timestamps

00:49 – Why it is important to Increase Diversity in Clinical Studies

01:31 – Statutory Requirements to Increase Diversity in Drug Development

04:44 – Drug Trials Snapshots (DTS)

17:18 – Summary

18:16 – Questions

Speakers:

Aden S. Asefa, MPH
Drug Trials Snapshot Lead
Office of Drug Evaluation Sciences (ODES)
Office of New Drugs (OND)
Center for Drug Evaluation and Research (CDER) | FDA

Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/regulatory-education-industry-redi-annual-conference-2024-innovation-medical-product-development

-----------------------

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2024 Playlist - https://www.youtube.com/playlist?list=PLey4Qe-Uxcxaf1HvpvnKO8-n8u9QW412g
SBIA LinkedIn - https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter - https://twitter.com/FDA_Drug_Info
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367